Compugen (CGEN) Competitors $1.78 +0.04 (+2.30%) Closing price 07/3/2025 02:20 PM EasternExtended Trading$1.79 +0.01 (+0.51%) As of 07/3/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEN vs. EOLS, UPB, XNCR, SAGE, KALV, DNTH, RLAY, IOVA, AMLX, and DNAShould you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Evolus (EOLS), Upstream Bio (UPB), Xencor (XNCR), Sage Therapeutics (SAGE), KalVista Pharmaceuticals (KALV), Dianthus Therapeutics (DNTH), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry. Compugen vs. Its Competitors Evolus Upstream Bio Xencor Sage Therapeutics KalVista Pharmaceuticals Dianthus Therapeutics Relay Therapeutics Iovance Biotherapeutics Amylyx Pharmaceuticals Ginkgo Bioworks Compugen (NASDAQ:CGEN) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership. Is CGEN or EOLS more profitable? Evolus has a net margin of -20.40% compared to Compugen's net margin of -51.27%. Compugen's return on equity of -24.51% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Compugen-51.27% -24.51% -12.19% Evolus -20.40%-759.04%-20.14% Does the media refer more to CGEN or EOLS? In the previous week, Compugen's average media sentiment score of 0.00 equaled Evolus'average media sentiment score. Company Overall Sentiment Compugen Neutral Evolus Neutral Do insiders and institutionals hold more shares of CGEN or EOLS? 12.2% of Compugen shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 5.9% of Evolus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher earnings & valuation, CGEN or EOLS? Compugen has higher earnings, but lower revenue than Evolus. Compugen is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$27.86M5.70-$14.23M-$0.16-11.13Evolus$266.27M2.24-$50.42M-$0.89-10.42 Do analysts recommend CGEN or EOLS? Compugen currently has a consensus target price of $4.00, suggesting a potential upside of 124.72%. Evolus has a consensus target price of $23.75, suggesting a potential upside of 156.20%. Given Evolus' higher possible upside, analysts plainly believe Evolus is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Evolus 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, CGEN or EOLS? Compugen has a beta of 2.57, suggesting that its share price is 157% more volatile than the S&P 500. Comparatively, Evolus has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. SummaryCompugen beats Evolus on 7 of the 13 factors compared between the two stocks. Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEN vs. The Competition Export to ExcelMetricCompugenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$157.06M$2.90B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-11.1321.5627.5820.25Price / Sales5.70281.07417.23118.60Price / CashN/A42.7336.8958.07Price / Book2.877.518.035.67Net Income-$14.23M-$55.05M$3.18B$249.21M7 Day Performance7.23%4.61%2.91%3.28%1 Month Performance4.09%4.72%3.72%5.56%1 Year Performance14.10%5.92%36.04%21.13% Compugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGENCompugen1.5764 of 5 stars$1.78+2.3%$4.00+124.7%+6.6%$157.06M$27.86M-11.1370EOLSEvolus3.606 of 5 stars$9.21+0.8%$23.75+157.9%-15.7%$589.31M$266.27M-10.35170Positive NewsUPBUpstream BioN/A$10.98+0.5%$56.50+414.6%N/A$587.97M$2.37M0.0038XNCRXencor4.0316 of 5 stars$7.86-3.4%$28.00+256.2%-54.8%$579.33M$110.49M-2.57280SAGESage Therapeutics3.2416 of 5 stars$9.12-0.3%$8.93-2.0%-13.4%$572.98M$41.24M-1.57690High Trading VolumeKALVKalVista Pharmaceuticals4.1734 of 5 stars$11.31-0.9%$24.83+119.6%+1.5%$567.26MN/A-3.04100Upcoming EarningsDNTHDianthus Therapeutics1.6041 of 5 stars$18.63+5.7%$53.00+184.5%-27.7%$566.98M$6.24M0.0080News CoverageAnalyst ForecastAnalyst RevisionRLAYRelay Therapeutics2.1375 of 5 stars$3.46+4.8%$17.67+410.6%-42.3%$565.77M$10.01M-1.55330IOVAIovance Biotherapeutics4.71 of 5 stars$1.72+1.8%$12.22+610.6%-76.3%$564.35M$164.07M-1.39500AMLXAmylyx Pharmaceuticals3.5163 of 5 stars$6.41+1.3%$11.00+71.6%+255.9%$564.26M$87.37M-2.06200DNAGinkgo Bioworks1.1251 of 5 stars$11.29+19.3%$5.77-48.9%N/A$553.71M$227.04M-1.23640Gap Up Related Companies and Tools Related Companies Evolus Alternatives Upstream Bio Alternatives Xencor Alternatives Sage Therapeutics Alternatives KalVista Pharmaceuticals Alternatives Dianthus Therapeutics Alternatives Relay Therapeutics Alternatives Iovance Biotherapeutics Alternatives Amylyx Pharmaceuticals Alternatives Ginkgo Bioworks Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGEN Stock Alerts